Navigation Links
People prefer 'carrots' to 'sticks' when it comes to healthcare incentives
Date:6/26/2013

To keep costs low, companies often incentivize healthy lifestyles. Now, new research suggests that how these incentives are framed as benefits for healthy-weight people or penalties for overweight people makes a big difference.

The research, published in Psychological Science, a journal of the Association for Psychological Science, shows that policies that carry higher premiums for overweight individuals are perceived as punishing and stigmatizing.

Researcher David Tannenbaum of the Anderson School of Management at the University of California, Los Angeles wanted to investigate how framing healthcare incentives might influence people's attitudes toward the incentives.

"Two frames that are logically equivalent can communicate qualitatively different messages," Tannenbaum explains.

In the first study, 126 participants read about a fictional company grappling with managing their employee health-care policy. They were told that the company was facing rising healthcare costs, due in part to an increasing percentage of overweight employees, and were shown one of four final policy decisions.

The "carrot" plan gave a $500 premium reduction to healthy-weight people, while the "stick" plan increased premiums for overweight people by $500. The two plans were functionally equivalent, structured such that healthy-weight employees always paid $2000 per year in healthcare costs, and overweight employees always paid $2500 per year in healthcare costs.

There were also two additional "stick" plans that resulted in a $2400 premium for overweight people.

Participants were more likely to see the "stick" plans as punishment for being overweight and were less likely to endorse them.

But they didn't appear to differentiate between the three "stick" plans despite the $100 premium difference. Instead, they seemed to evaluate the plans on moral grounds, deciding that punishing someone for being overweight
'/>"/>

Contact: Anna Mikulak
amikulak@psychologicalscience.org
202-293-9300
Association for Psychological Science
Source:Eurekalert

Page: 1 2

Related medicine news :

1. For Fourth of July, People from over 190 Countries Shared Emotions of Pride, Patriotism and Celebration From 123Greetings.com
2. Lakeland, Florida Joins Best Halfway House Recovery Network, Providing Resources for People Seeking More Support in Their Recovery from Drug and Alcohol Addiction
3. Yoga Course
4. “Shapeshifter Yoga” Teaches People How to Learn Yoga Easily and Quickly – V-kool
5. Healthy Food Recipes
6. “Honey Garlic And Vinegar Miracle” Teaches People How To Make Healthy Meals – Health Review
7. New Mirena IUD Complications Lawsuits Allegations Report: Resource4thePeople Reports Important Multidistrict Litigation Hearing Scheduled
8. Key West, Florida Joins Best Halfway House Recovery Network, Helping People Seek Further Recovery from Drug and Alcohol Addiction
9. David Icke to Launch Global TV and Radio Station Called The People's Voice
10. Arc Creates Huge Mosaic Mural to Highlight the Need for Greater Respect of People with Disabilities
11. New Evidence Based Information on Treatment for Over 8 Million People in the U.S. Affected With Disorders of the Vestibular System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... 30, 2014 Recently, iFitDress.com, a well-known wedding ... satin bridal gowns . Aside from this, it has ... up to 68 percent off. All of its old and ... The company’s sales representative says excitedly, “We are pleased to ... new range, there are a lot of amazing items. It ...
(Date:7/29/2014)... St. Petersburg, FL (PRWEB) July 30, 2014 Phytceramides ... explains how and why in her new book. , Today is ... Phytoceramides: Anti Aging At Its Best . The book is ... larger skin care book, but felt that Phytoceramides were ... sense to bring out this focused book now," says Kathy Heshelow, ...
(Date:7/29/2014)... (PRWEB) July 30, 2014 Dignity Sciences ... successful completion of a Phase I trial with DS107G, ... , This study was a randomized, placebo-controlled, double-blind, single-ascending ... the safety, pharmacokinetics and effect of food on DS107G ... benign safety profile of DGLA following both single and ...
(Date:7/29/2014)... VA (PRWEB) July 29, 2014 The ... members of the Deadliest Cancer Coalition, led advocacy efforts ... officials in the newly established Congressional Caucus on the Deadliest ... efforts, the caucus now features the following 20 members: , ... Eshoo (CA-18) – May 2, 2014, Rep. Zoe Lofgren (CA-19) ...
(Date:7/29/2014)... researchers say they have discovered a chemical alteration in ... if confirmed in larger studies, could give doctors a ... of attempting suicide. , The discovery, described online in ... changes in a gene involved in the function of ... role in turning what might otherwise be an unremarkable ...
Breaking Medicine News(10 mins):Health News:Cheap Satin Bridal Gowns Recently Provided By Well-known Supplier iFitDress.com 2Health News:Last Day New Book Is Available at No Cost: Phytoceramides, Anti Aging At Its Best by Sublime Beauty Founder® Kathy Heshelow 2Health News:Last Day New Book Is Available at No Cost: Phytoceramides, Anti Aging At Its Best by Sublime Beauty Founder® Kathy Heshelow 3Health News:DS107G-01 – Successful Completion of Phase I Oral DGLA Clinical Trial 2Health News:Mesothelioma Organization Works to Add Members to ‘Deadliest Cancer Caucus’ 2Health News:Mesothelioma Organization Works to Add Members to ‘Deadliest Cancer Caucus’ 3Health News:A blood test for suicide? 2Health News:A blood test for suicide? 3
... them women, suffer from lupus, a disease where the ... week marks a significant step forward in understanding how ... new studies identifying genes involved in this often debilitating ... of the division of Rheumatology and director of Rheumatology ...
... length, group advises , , SUNDAY, Jan. 20 (HealthDay News) -- ... illness, it can be a challenge to take care of ... serious complications, says the American Diabetes Association. , "People ... weather," Ann Albright, the ADA,s president of health care and ...
... Jan. 18 Following the New Hampshire primary,a headline ... life.", Ironically, Joe Dolphin, who announced his endorsement ... a lung transplant, is also hoping,to receive breath that ... leader has suffered for many years with AAT (Alpha-1 ...
... has been named the national lead center for ... pediatric heart pump called Berlin Heart EXCOR® Pediatric ... MD, chief of pediatric and congenital heart surgery ... Department of Surgery at Baylor College of Medicine, ...
... Pharmacyclics,Inc. (Nasdaq: PCYC ) today announced ... its second quarter 2008 financial results and achievements ... (1:30 p.m. PDT)., To participate in the ... 706-758-3306 for international callers and reference,conference passcode, 31926585. ...
... from,the Academy of Columbus, an Imagine charter school, will ... A Smile! Day state kick-off in,Columbus on Friday, Feb.1., ... in the Atrium at the,Ohio Statehouse with dentists, dental ... of Dentistry, legislators and other,dignitaries participating. At the event, ...
Cached Medicine News:Health News:NEJM editorial on significance and limitations of new lupus gene expression research 2Health News:NEJM editorial on significance and limitations of new lupus gene expression research 3Health News:NEJM editorial on significance and limitations of new lupus gene expression research 4Health News:Illness Presents Diabetics With Special Challenges 2Health News:Long-Time San Diego Community Leader, Transplant Patient, Joe Dolphin, Endorses John Mccain 2Health News:National study will look at German-made heart pump for children needing heart transplants 2Health News:National study will look at German-made heart pump for children needing heart transplants 3Health News:Statehouse Atrium to be Site for Children's Dental Access Event - Ohio Legislators to Mingle With Children and Dentists for This Free Care Event! 2
(Date:7/29/2014)... N.J., July 29, 2014  Covance Inc. (NYSE: ... quarter ended June 30, 2014.  Net revenue was $639 ... 2013.  On a GAAP basis, the company reported earnings ... The company reported pro forma earnings per diluted share ... 2013. Pro forma results exclude asset impairment charges totaling ...
(Date:7/29/2014)... 29  2014 ISPE—the International Society for Pharmaceutical ... Bournas as President and CEO, succeeding ... the Society last fall.  Mr. Bournas takes the ... healthcare association industry as well as significant international ... vision for the expansion of its global initiatives ...
(Date:7/29/2014)... -- Roche (SIX: RO, ROG; OTCQX: RHHBY) launched its presence ... Clinical Lab Expo today by unveiling two booths (#1209 ... partnering with customers to redefine the value of the ... that they,re looking for a partner to help them ... offices," said Jack Phillips , president and CEO ...
Breaking Medicine Technology:Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 2Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 3Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 4Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 5Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 6Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 7Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 8Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 9Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 10Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 11Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 12Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 13Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 14Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 15Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 16Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 17Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 18Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 19Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 20Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 21Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 22Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 23Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 24ISPE Hires Healthcare Association Exec as CEO 2ISPE Hires Healthcare Association Exec as CEO 3Roche focuses on partnering with customers to redefine the value of the laboratory at the AACC 2014 Clinical Lab Expo 2Roche focuses on partnering with customers to redefine the value of the laboratory at the AACC 2014 Clinical Lab Expo 3Roche focuses on partnering with customers to redefine the value of the laboratory at the AACC 2014 Clinical Lab Expo 4
... -- China Medical Technologies, Inc. (the "Company") (Nasdaq: ... in-vitro diagnostic ("IVD") company, today announced that its ... ("GP Medical") and Beijing Yuande Bio-Medical Engineering Co., ... 415th, respectively, in the Deloitte Technology Fast 500 ...
... SUNNYVALE, Calif., Dec. 5, 2010 Pharmacyclics, Inc. (Nasdaq: ... Chronic Lymphocytic Leukemia (CLL) presentations at the American Society ... PCI-32765.  Two presentations report preclinical data, and one presentation ... patients with CLL or Small Lymphocytic Lymphoma (SLL) treated ...
Cached Medicine Technology:China Medical Technologies Announces its Subsidiaries, GP Medical and Beijing Yuande, Ranked 12th and 415th, respectively, in Deloitte Technology Fast 500 Asia Pacific 2010 Program 2Pharmacyclics Reports CLL Results from Preclinical and Clinical Studies of its Btk Inhibitor PCI-32765 2Pharmacyclics Reports CLL Results from Preclinical and Clinical Studies of its Btk Inhibitor PCI-32765 3Pharmacyclics Reports CLL Results from Preclinical and Clinical Studies of its Btk Inhibitor PCI-32765 4Pharmacyclics Reports CLL Results from Preclinical and Clinical Studies of its Btk Inhibitor PCI-32765 5Pharmacyclics Reports CLL Results from Preclinical and Clinical Studies of its Btk Inhibitor PCI-32765 6Pharmacyclics Reports CLL Results from Preclinical and Clinical Studies of its Btk Inhibitor PCI-32765 7
Molt periosteal elevator #9, 18.5 cm, 7-1/4"....
Periosteal elevator #9, 18 cm, 7"....
Full curve periosteal elevator - cervical - sharp, round tip, length 184 mm (7 1/4")....
... The Frontier Anterior Deformity System ... Kass, Moss Miami, and Isola ... thoracoscopic procedures to deliver unsurpassed versatility, ... the highest level of versatility for ...
Medicine Products: